OncRef

Clinical Trial: NCT05814354

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Jiangsu HengRui Medicine Co., Ltd.
Information Provided By:Jiangsu HengRui Medicine Co., Ltd.
Last Update Posted:2026-08-06

Study Overview

Brief Summary

The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.

Official Title

A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: SHR-A1811
  • Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Other Study ID Numbers

  • SHR-A1811-III-306

Start Date (Actual)

2023-06-30

Primary Completion Date (Actual)

2026-03-20

Study Completion Date (Estimated)

2028-06-30

Enrollment (Actual)

551

Study Type

Interventional

Phase

Phase 3